A084990 Stock Overview
Develops biologic and natural nutraceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Helixmith Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,670.00 |
| 52 Week High | ₩7,440.00 |
| 52 Week Low | ₩2,500.00 |
| Beta | 1.1 |
| 1 Month Change | -11.30% |
| 3 Month Change | -21.01% |
| 1 Year Change | -49.72% |
| 3 Year Change | -88.46% |
| 5 Year Change | -95.87% |
| Change since IPO | -82.00% |
Recent News & Updates
Shareholder Returns
| A084990 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -4.8% | -3.9% | -3.7% |
| 1Y | -49.7% | 15.6% | -10.4% |
Return vs Industry: A084990 underperformed the KR Biotechs industry which returned 15.6% over the past year.
Return vs Market: A084990 underperformed the KR Market which returned -10.4% over the past year.
Price Volatility
| A084990 volatility | |
|---|---|
| A084990 Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A084990 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A084990's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 72 | Ji-Wook Jeong | www.helixmith.com |
Helixmith Co., Ltd develops biologic and natural nutraceutical products. The company offers LAYLA Tab for osteoarthritis; Allex and Allex i for hypersensitivity improvement; and Mnemosyne for memory improvement. Its lead gene therapy product is Engensis (VM202), which is in a phase III clinical trial for diabetic peripheral neuropathy and diabetic foot ulcer; a phase II clinical trial for amyotrophic lateral sclerosis (ALS) and claudication; and a phase I clinical trial for charcot-marie-tooth disease and coronary artery disease.
Helixmith Co., Ltd Fundamentals Summary
| A084990 fundamental statistics | |
|---|---|
| Market cap | ₩122.95b |
| Earnings (TTM) | -₩49.94b |
| Revenue (TTM) | ₩3.88b |
31.7x
P/S Ratio-2.5x
P/E RatioIs A084990 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A084990 income statement (TTM) | |
|---|---|
| Revenue | ₩3.88b |
| Cost of Revenue | ₩2.39b |
| Gross Profit | ₩1.49b |
| Other Expenses | ₩51.43b |
| Earnings | -₩49.94b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08k |
| Gross Margin | 38.43% |
| Net Profit Margin | -1,287.18% |
| Debt/Equity Ratio | 0.1% |
How did A084990 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 16:53 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Helixmith Co., Ltd is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sangsoo Kim | Goldman Sachs |
| Jaeik Kim | iM Securities |
| Wan Ku | NH Investment & Securities Co., Ltd. |